At Filament, we are proud to hold a portfolio of seven patents issued by the Canadian Intellectual Property Office and the United States Patent and Trademark Office.
Filament’s robust portfolio reflects the strength of both our intellectual property strategy and our drug development platform.
But why are patents so valuable, particularly in the psychedelics industry? Our CEO Ben Lightburn sat down to explain:
At Filament, we are proud to hold a portfolio of seven patents issued by the Canadian Intellectual Property Office and the United States Patent and Trademark Office.
Filament’s robust portfolio reflects the strength of both our intellectual property strategy and our drug development platform.
But why are patents so valuable, particularly in the psychedelics industry? Our CEO Ben Lightburn sat down to explain:
